T1	CHEM 1 14	Lercanidipino
#1	AnnotatorNotes T1	C0526399; lercanidipine; Organic Chemical · Pharmacologic Substance
T2	DISO 28 38	diabéticos
#2	AnnotatorNotes T2	C0011849; Diabetes Mellitus; Disease or Syndrome | C0241863; Diabetic; Finding | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T3	DISO 43 62	insuficiencia renal
#3	AnnotatorNotes T3	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T4	PROC 107 127	evaluar la seguridad
#4	AnnotatorNotes T4	C1705187; Safety Study; Research Activity
T5	CHEM 140 176	bloqueante de los canales del calcio
#5	AnnotatorNotes T5	C0006684; Calcium Channel Blockers; Pharmacologic Substance
T6	CHEM 178 191	lercanidipino
#6	AnnotatorNotes T6	C0526399; lercanidipine; Organic Chemical · Pharmacologic Substance
T7	DISO 199 226	insuficiencia renal crónica
#7	AnnotatorNotes T7	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T8	PROC 298 306	tratados
#8	AnnotatorNotes T8	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T9	ANAT 336 359	eje renina-angiotensina
#9	AnnotatorNotes T9	C0035096; Renin-angiotensin system; Body System (?)
T10	CHEM 311 319	fármacos
#10	AnnotatorNotes T10	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T11	CHEM 340 346	renina
#11	AnnotatorNotes T11	C0035094; Renin; Amino Acid, Peptide, or Protein · Enzyme
T12	CHEM 347 359	angiotensina
#12	AnnotatorNotes T12	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T13	DISO 422 432	diabéticos
#13	AnnotatorNotes T13	C0011849; Diabetes Mellitus; Disease or Syndrome | C0241863; Diabetic; Finding | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T14	DISO 510 520	diabéticos
#14	AnnotatorNotes T14	C0011849; Diabetes Mellitus; Disease or Syndrome | C0241863; Diabetic; Finding | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T15	DISO 525 544	insuficiencia renal
#15	AnnotatorNotes T15	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T16	PROC 684 692	tratados
#16	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	PROC 608 634	aclaramiento de creatinina
#17	AnnotatorNotes T17	C0373595; Creatinine clearance measurement; Laboratory Procedure
T18	CHEM 697 701	IECA
#18	AnnotatorNotes T18	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T19	CHEM 736 746	medicación
#19	AnnotatorNotes T19	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T20	PROC 833 844	seguimiento
#20	AnnotatorNotes T20	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T21	PROC 934 945	tratamiento
#21	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	PROC 981 983	PA
#22	AnnotatorNotes T22	C0005824; Blood pressure determination; Health Care Activity
T23	PROC 1122 1124	PA
#23	AnnotatorNotes T23	C0005824; Blood pressure determination; Health Care Activity
T24	PROC 1178 1180	PA
#24	AnnotatorNotes T24	C0005824; Blood pressure determination; Health Care Activity
T25	PROC 1247 1249	PA
#25	AnnotatorNotes T25	C0005824; Blood pressure determination; Health Care Activity
T26	DISO 1316 1335	reacciones adversas
#26	AnnotatorNotes T26	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T27	DISO 1367 1372	edema
#27	AnnotatorNotes T27	C0013604; Edema; Pathologic Function
T28	CHEM 1377 1387	creatinina
#28	AnnotatorNotes T28	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T29	ANAT 1388 1398	plasmática
#29	AnnotatorNotes T29	C0032105; Plasma; Body Substance
T30	PROC 1485 1511	aclaramiento de creatinina
#30	AnnotatorNotes T30	C0373595; Creatinine clearance measurement; Laboratory Procedure
T31	CHEM 1560 1573	lercanidipino
#31	AnnotatorNotes T31	C0526399; lercanidipine; Organic Chemical · Pharmacologic Substance
T32	ANAT 1638 1645	renales
#32	AnnotatorNotes T32	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T33	DISO 1673 1679	edemas
#33	AnnotatorNotes T33	C0013604; Edema; Pathologic Function
T34	DISO 1694 1713	insuficiencia renal
#34	AnnotatorNotes T34	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T35	DISO 1719 1727	diabetes
#35	AnnotatorNotes T35	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T36	PROC 1848 1850	PA
#36	AnnotatorNotes T36	C0005824; Blood pressure determination; Health Care Activity
T37	ANAT 57 62	renal
#37	AnnotatorNotes T37	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T38	ANAT 213 218	renal
#38	AnnotatorNotes T38	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T39	ANAT 275 280	renal
#39	AnnotatorNotes T39	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T40	ANAT 539 544	renal
#40	AnnotatorNotes T40	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T41	PROC 546 556	creatinina
#41	AnnotatorNotes T41	C0201975; Creatinine measurement; Laboratory Procedure
T42	CHEM 624 634	creatinina
#42	AnnotatorNotes T42	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T43	CHEM 704 730	antagonistas de receptores
T44	CHEM 807 817	diuréticos
#43	AnnotatorNotes T44	C0012798; Diuretics; Pharmacologic Substance
T45	CHEM 950 963	lercanidipino
#44	AnnotatorNotes T45	C0526399; lercanidipine; Organic Chemical · Pharmacologic Substance
T46	DISO 1144 1152	enfermos
#45	AnnotatorNotes T46	C0012634; Disease; Disease or Syndrome
T47	PROC 1377 1398	creatinina plasmática
#46	AnnotatorNotes T47	C1278055; plasma creatinine measurement; Laboratory Procedure
T48	CHEM 1501 1511	creatinina
#47	AnnotatorNotes T48	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T49	ANAT 1708 1713	renal
#48	AnnotatorNotes T49	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T50	LIVB 18 27	pacientes
#49	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Duration 219 226	crónica
#50	AnnotatorNotes T51	C0205191; chronic; Temporal Concept
T53	LIVB 288 297	pacientes
#51	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 412 421	pacientes
#52	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	LIVB 500 509	pacientes
#53	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T57	LIVB 572 579	varones
#54	AnnotatorNotes T57	C0025266; Male population group; Population Group
T58	LIVB 597 604	mujeres
#55	AnnotatorNotes T58	C0043210; Woman; Population Group
T61	LIVB 659 668	pacientes
#56	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	Neg_cue 782 785	sin
T65	LIVB 850 859	pacientes
#57	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T68	LIVB 1224 1233	pacientes
#58	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	Neg_cue 1299 1301	No
T75	LIVB 1628 1637	pacientes
#59	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T76	Neg_cue 1661 1672	ausencia de
T77	LIVB 1735 1744	pacientes
#60	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T78	LIVB 1820 1829	pacientes
#61	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T79	PHYS 267 280	función renal
#62	AnnotatorNotes T79	C0232804; Renal function; Organ or Tissue Function
T52	Duration 900 914	1, 3 y 6 meses
T56	Neg_cue 1336 1338	ni
T59	PROC 489 496	reclutó
#63	AnnotatorNotes T59	C0242800; Patient Recruitment; Research Activity
A1	Assertion T44 Negated
A2	Assertion T26 Negated
A3	Assertion T33 Negated
A4	Assertion T27 Negated
R1	Location_of Arg1:T37 Arg2:T3	
T60	Observation 241 257	efecto protector
A5	Assertion T60 Speculated
T63	Spec_cue 233 240	posible
R2	Speculation Arg1:T63 Arg2:T60	
R3	Experiences Arg1:T53 Arg2:T60	
R4	Experiences Arg1:T53 Arg2:T79	
R5	Location_of Arg1:T39 Arg2:T79	
R6	Experiences Arg1:T53 Arg2:T8	
R7	Used_for Arg1:T10 Arg2:T8	
R8	Experiences Arg1:T50 Arg2:T1	
R9	Experiences Arg1:T50 Arg2:T2	
R10	Overlap Arg1:T2 Arg2:T3	
R11	Experiences Arg1:T50 Arg2:T3	
R12	Location_of Arg1:T38 Arg2:T7	
R13	Has_Duration_or_Interval Arg1:T7 Arg2:T51	
R14	Causes Arg1:T6 Arg2:T60	
R15	Causes Arg1:T5 Arg2:T60	
R16	Experiences Arg1:T53 Arg2:T5	
R17	Experiences Arg1:T53 Arg2:T6	
R18	Experiences Arg1:T53 Arg2:T7	
R21	Experiences Arg1:T54 Arg2:T13	
R22	Experiences Arg1:T55 Arg2:T59	
R23	Experiences Arg1:T55 Arg2:T14	
R24	Overlap Arg1:T14 Arg2:T15	
R25	Experiences Arg1:T55 Arg2:T15	
R26	Location_of Arg1:T40 Arg2:T15	
T64	Result_or_Value 557 568	> 1,4 mg/dl
R27	Has_Result_or_Value Arg1:T41 Arg2:T64	
R28	Experiences Arg1:T57 Arg2:T41	
R29	Experiences Arg1:T58 Arg2:T41	
T66	Result_or_Value 582 593	> 1,2 mg/dl
R30	Has_Result_or_Value Arg1:T41 Arg2:T66	
T67	Result_or_Value 635 646	< 70 ml/min
R31	Has_Result_or_Value Arg1:T17 Arg2:T67	
R32	Experiences Arg1:T57 Arg2:T17	
R33	Experiences Arg1:T58 Arg2:T17	
R34	Experiences Arg1:T55 Arg2:T41	
R35	Experiences Arg1:T55 Arg2:T17	
R36	Experiences Arg1:T61 Arg2:T16	
R37	Used_for Arg1:T18 Arg2:T16	
R38	Used_for Arg1:T43 Arg2:T16	
R39	Used_for Arg1:T19 Arg2:T16	
R40	Experiences Arg1:T61 Arg2:T19	
T70	Observation 736 757	medicación se mantuvo
#64	AnnotatorNotes T70	C3494713; Medication therapy continued; Finding
R41	Experiences Arg1:T61 Arg2:T70	
T71	PROC 773 780	estudio
#65	AnnotatorNotes T71	C0681814; research study; Research Activity
R42	Overlap Arg1:T70 Arg2:T71	
R43	Negation Arg1:T62 Arg2:T44	
R44	Overlap Arg1:T44 Arg2:T20	
R45	Overlap Arg1:T71 Arg2:T20	
R46	Experiences Arg1:T61 Arg2:T44	
T72	PROC 865 874	evaluados
#66	AnnotatorNotes T72	C0220825; Evaluation; Health Care Activity | C1261322; Evaluation procedure; Health Care Activity
R47	Experiences Arg1:T65 Arg2:T72	
R48	Overlap Arg1:T72 Arg2:T52	
R49	After Arg1:T72 Arg2:T21	
T73	Quantifier_or_Qualifier 875 899	clínica y analíticamente
R50	Has_Quantifier_or_Qualifier Arg1:T72 Arg2:T73	
R51	Used_for Arg1:T45 Arg2:T21	
R52	Experiences Arg1:T65 Arg2:T21	
T74	Observation 981 993	PA se redujo
T80	Observation 1089 1100;1116 1124	reducciones de la PA
R54	Experiences Arg1:T68 Arg2:T25	
T81	Observation 1234 1249	redujeron su PA
R55	Experiences Arg1:T68 Arg2:T81	
R56	Negation Arg1:T69 Arg2:T26	
R57	Negation Arg1:T56 Arg2:T27	
T82	CONC 1339 1346	aumento
A6	Assertion T82 Negated
R58	Negation Arg1:T56 Arg2:T82	
#67	AnnotatorNotes T82	C0442805; Increase; Functional Concept
R59	Location_of Arg1:T29 Arg2:T47	
T83	Neg_cue 1417 1419	no
T84	CONC 1429 1439	modificado
A7	Assertion T84 Negated
#68	AnnotatorNotes T84	C1705241; Delta (difference); Quantitative Concept
R60	Negation Arg1:T83 Arg2:T84	
T85	CONC 1443 1460	final del estudio
#69	AnnotatorNotes T85	C2983670; Study End Date; Temporal Concept
R61	Overlap Arg1:T84 Arg2:T85	
R62	Overlap Arg1:T47 Arg2:T85	
R63	Overlap Arg1:T30 Arg2:T85	
R64	Experiences Arg1:T75 Arg2:T31	
R66	Negation Arg1:T76 Arg2:T33	
R65	Experiences Arg1:T75 Arg2:T33	
R67	Location_of Arg1:T49 Arg2:T34	
R68	Overlap Arg1:T34 Arg2:T35	
R69	Experiences Arg1:T75 Arg2:T34	
R70	Experiences Arg1:T75 Arg2:T35	
R71	Experiences Arg1:T77 Arg2:T35	
R72	Experiences Arg1:T77 Arg2:T34	
T86	Observation 1766 1787	respuesta hipotensora
T87	Quantifier_or_Qualifier 1760 1765	buena
R73	Has_Quantifier_or_Qualifier Arg1:T86 Arg2:T87	
R74	Experiences Arg1:T78 Arg2:T86	
R75	Experiences Arg1:T78 Arg2:T36	
R76	Overlap Arg1:T86 Arg2:T36	
T88	Quantifier_or_Qualifier 320 359	que bloquean el eje renina-angiotensina
R77	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T88	
T89	Quantifier_or_Qualifier 1181 1189	objetivo
R79	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T89	
T90	Quantifier_or_Qualifier 1851 1859	objetivo
R80	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T90	
#70	AnnotatorNotes T89	C1521840; Target; Functional Concept
#71	AnnotatorNotes T87	C0205170; Good; Qualitative Concept
#72	AnnotatorNotes T90	C1521840; Target; Functional Concept
#73	AnnotatorNotes T43	C5399721; Receptor Antagonist [APC]; Pharmacologic Substance
#74	AnnotatorNotes T60	C2712083; Actual Effective Protective Ability; Finding (?)
A8	Experiencer T50 Patient
A9	Experiencer T53 Patient
A10	Experiencer T54 Patient
A11	Experiencer T55 Patient
A12	Experiencer T58 Patient
A13	Experiencer T57 Patient
A14	Experiencer T61 Patient
A15	Experiencer T65 Patient
A16	Experiencer T68 Patient
A17	Experiencer T75 Patient
A18	Experiencer T77 Patient
A19	Experiencer T78 Patient
R19	Has_Result_or_Value Arg1:T22 Arg2:T74	
R20	Has_Result_or_Value Arg1:T23 Arg2:T80	
R53	Has_Result_or_Value Arg1:T25 Arg2:T81	
